About this document
Week 2 PPT Journal Club AO Xolair by alyssarobinson2812 is a document available to read on EtoBox.
The study evaluates the efficacy of omalizumab in patients with severe allergic asthma inadequately controlled by high-dose ICS and LABA therapy. Results showed a significant reduction in asthma exacerbation rates for the omalizumab group compared to placebo, with improvements in symptom severity and quality of life. Omalizumab is recommended as a biologic therapy option for patients with allergic asthma and elevated IgE levels.
- Author
- alyssarobinson2812
- Language
- EN